Biotech Values

[DewDiligence]

Thanks for the post about Zymo; however, I think the author overstates the case for Lambda to some degree. VRTX’s phase-2 trial with Telaprevir and VX-222 is not nearly as probative as the author contends, IMO; rather, VRTX’s results point to the likely requirement for a cocktail of HCV DAA’s to include at least three drugs, as is the case in HIV.